Navigation Links
Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
Date:4/10/2009

EXTON, Pa., April 10 /PRNewswire/ -- On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva (efalizumab, marketed by Genentech/Roche and Xoma) from the US market. The withdrawal comes after recent post-marketing reports of PML associated with Raptiva treatment.

BioTrends will field its fourth annual TreatmentTrends(TM): Psoriasis survey on April 13th with a special section dedicated to the impact of the Raptiva withdrawal. The on-line survey will be completed by 150 clinical dermatologists and is structured to assess treatment prevalence and brand use for topical, oral, and biologic agents. A comprehensive attribute analysis is provided for each class to indicate areas of unmet need and market share projections for the next six months. In addition, awareness and interest in products in late stage development, such as Centocor's STELARA (ustekinumab) and Abbott's ABT-874 is assessed. The report will be published in early May.

A second report offered by BioTrends, ChartTrends(TM): Biologics in Psoriasis, is a report that is based on actual patient level audit data collected through a proprietary audit tool. In this report, 1000 patients who are currently being treated with biologic agents will be reviewed to analyze the treatment algorithm that culminates in the use of biologic agents, patient demographics/co-morbidities associated with specific biologic brand use, product switching incidence and rationale, and concomitant medications. A special section focused on switches from Raptiva will be included to understand if these patients migrate to other biologic brands or are discontinued altogether from biologic therapy. This report will be published in early June.

According to last year's TreatmentTrends(TM): Psoriasis report, market share for Raptiva had steadily declined since 2006 and only 44% of the dermatologists surveyed were using the product in their practices in April 2008. Amgen/Wyeth's Enbrel and Abbott's Humira, the most frequently prescribed biologics in psoriasis, were rated significantly higher than Raptiva on nearly all of the most important attributes. However, Raptiva held a competitive advantage over all biologic competitors on its efficacy in palmo-plantar psoriasis.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
2. UD researchers race ahead with latest spintronics achievement
3. Digital Healthcare Announces Cincinnati Eye Institute is Latest Retasure Reading Center
4. 49th Annual Meeting of the American Society of Hematology Will Feature the Latest Research in Blood Diseases
5. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
6. PacifiCare Capitulates to Latest Patient Revolt
7. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
8. Carbon nanotube measurements: latest in NIST how-to series
9. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
10. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
11. Latest Sleep Disorder Technology Tested With SleepQuest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):